Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Breakthrough Genomics, |
RCV004692624 | SCV005190063 | uncertain significance | not provided | criteria provided, single submitter | not provided | ||
Department of Pathology and Laboratory Medicine, |
RCV001354342 | SCV001548937 | uncertain significance | PULMONARY ALVEOLAR MICROLITHIASIS | no assertion criteria provided | clinical testing | The SLC34A2 p.T154A variant was not identified in the literature nor was it identified in ClinVar. The variant was identified in dbSNP (ID: rs201866415) and in control databases in 6 of 282646 chromosomes at a frequency of 0.00002123, where it was observed only in the European (non-Finnish) population in 6 of 129066 chromosomes (freq: 0.00004649) (Genome Aggregation Database March 6, 2019, v2.1.1). The p.T154 residue is conserved in mammals and more distantly related organisms, and computational analyses (MUT Assesor, PolyPhen-2, SIFT, MutationTaster, Revel, FATHMM, MetaLR, DANN) suggest that the variant may impact the protein; however, this information is not predictive enough to assume pathogenicity. The variant occurs outside of the splicing consensus sequence and in silico or computational prediction software programs (Splice AI exome) do not predict a difference in splicing. In summary, based on the above information the clinical significance of this variant cannot be determined with certainty at this time. This variant is classified as a variant of uncertain significance. |